Read Part 1 here.
Leading experts in vitiligo recently hosted a series of Dermatology Times Case-Based Roundtables in cities around the country to discuss approaches to complex cases, understand challenges across different age groups and skin types, and explore the conditions impact on patient well-being.
Roundtable hosts included Benjamin Lockshin, MD, FAAD, in Washington, DC; Heather Woolery-Lloyd, MD, in Miami, Florida; Elizabeth Kiracofe, MD, FAAD, in Chicago, Illinois; James Song, MD, in Seattle, Washington; and Karan Lal, DO, FAAD, in Scottsdale, Arizona. Here are a few additional cases that the roundtable participants delved into.
A 35-year-old Whiteman with Fitzpatrick skin type II and vitiligo on multiple areas of his body, particularly the dorsal hands and forearms, was presented to Chicago roundtable participants. The focus was on unstable vitiligo, characterized by changing depigmented patches. The challenges that were discussed included managing the inflammation that causes vitiligo to worsen. The group reached a consensus on usingoral dexamethasone as the primary treatment for actively depigmenting or unstable vitiligo.
The patient, an outdoor enthusiast and guitarist, faced challenges with topical treatments due to lifestyle constraints. The discussion emphasized the significant benefits of light therapy for vitiligo, recommending sunlight exposure when possible or using specific narrowband wavelengths and UVB light boxes. The contradictory nature of advising careful sun protection while using ultraviolet radiation for treatment was highlighted.
The stability of vitiligo was discussed in terms of satellite lesions, sharp borders, and pigment network absence as markers of stability. The patient had previously used topical corticosteroids and calcineurin inhibitors but, due to his lifestyle, switched to topical ruxolitinib, which showed improvement in adherence and repigmentation.
The conversation touched on the challenges of obtaining insurance coverage for topical ruxolitinib despite its US Food and Drug Administration (FDA) approval. The group shared experiences from different regions.
I know just from a policy perspective [that] there [are] still some states that consider vitiligo a cosmetic condition. But we all experienced that patients really like the vehicle of topical ruxolitinib and are seeing results with it. The biggest hesitation with using it issimply theres no hesitation with using it. The biggest [universal] pause was [that]...unfortunately, sometimes it can be hard to get covered, Kiracofe said.
Despite coverage difficulties, the group expressed the positive response from patients to topical ruxolitinib, emphasizing its importance as a novel therapy.
Lal presented a case involving a 51-year-old African American man with persistent depigmented patches, impacting his self-esteem. Despite considering topical ruxolitinib as the ideal treatment, Medicaid limitations categorized vitiligo as a cosmetic disease, hindering insurance coverage. The patient initially underwent alternative therapies, including topical steroids and tacrolimus, with minimal improvement.
In our discussion, most patients [of colleagues] were using topical mometasone and topical hydrocortisone 2.5% both in ointment formulations as topical steroids of choice for starting their treatment regimen for vitiligo, and including topical tacrolimus as steroid sparing therapy, where people alternate topical tacrolimus along with topical steroids to reduce the side effects from topical steroids specifically clench acacias, skin thinning, atrophy and stretch marks, Lal explained.
Challenges in accessing phototherapy due to Medicaid restrictions were also discussed. After 3 months, the patient received topical ruxolitinib, resulting in focused improvements on cosmetically sensitive areas. The discussion emphasized the success of topical ruxolitinib, but acknowledged challenges in insurance approval for Medicaid recipients. Side effects, specifically folliculitis with topical ruxolitinib, were addressed, emphasizing management strategies without discontinuing therapy. The discussion concluded with insights into prior authorization processes and the use of specific pharmacies for medication access. Overall, the Scottsdale roundtable participants expressed success with combination therapies and emphasized the need for a holistic approach in vitiligo management.
A 23-year-old African American man with Fitzpatrick skin type VI presented with deep pigmented patches on visible areas such as thehands, arms, neck, and face. The contrast between normal skin and vitiligo patches were particularly noticeable due to his dark complexion, impacting his quality of life, especially as an active sports enthusiast. The continued discussion in Seattle focused on treating patients with different skin colors, considering that darker skin may make vitiligo more noticeable.
Initial treatment involved topical corticosteroids and calcineurin inhibitors, with the addition of phototherapy when the response was limited. However, the patient developed extensive vitiligo involvement, prompting a shift to alternative treatments. Stable vitiligo was defined as 1 to 2years without new areas of vitiligo.
The panel discussed oral steroids as an option for unstable vitiligo, with varying dosing regimens. The patient received 12 weeks of weekly dexamethasone dosing, followed by repigmentation efforts. Later, due to the patients preference and difficulty with topical treatments, they switched to topical ruxolitinib.
Concerns were raised about the box warning associated with topical ruxolitinib, and the discussion highlighted strategies to communicate the warning to patients without causing undue alarm. Absorption rates of the topical form compared with the oral version were discussed, indicating lower systemic exposure and reduced risk of cumulative effects.
Access to topical ruxolitinib was a significant point of discussion, with practitioners sharing their experiences. Its important to make sure we always prescribe a topical corticosteroid and a topical calcineurin inhibitor. Then we document that this is nonsegmental vitiligo in the note, rather than segmental vitiligo, which topical ruxolitinib is not approved for, Song said.We alsoneed to be very clear when we write topical ruxolitinib for vitiligo. It shouldnt be greater than 10% BSA [body surface area], which is different than what we see with atopic dermatitis, which is no greater than 20% BSA.Sometimes if you mix those 2up, that can lead to a drug denial. Lastly, there are some payers that consider vitiligo to still be cosmetic, so sometimes they will deny ruxolitinib.... We talked about resources we can use to get these medications approved. The patient can get a passive letter of medical necessity that we can print out, [going] over why vitiligo is not a cosmetic disease.
Case-Based Roundtable moderators across the country reflected on 3 main take-home points to remain cognizant of when meeting a patient with vitiligo.
Read more:
- American Academy of Dermatology Association Statement on Reports on Counterfeit Injectables - Newswise - April 15th, 2024 [April 15th, 2024]
- Surface Area of IL-23's Epitope Influences Short- and Long-Term Responses for IL-23 Inhibitors in Plaque Psoriasis - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Atopic Dermatitis (Eczema): 5 Top Self-Care Tips - Everyday Health - April 15th, 2024 [April 15th, 2024]
- Derm In The News: April 7-13 - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Generative models improve fairness of medical classifiers under distribution shifts - Nature.com - April 15th, 2024 [April 15th, 2024]
- A 30-Year-Old White Female Presented With a 4-Month History of Scaly, Erythematous Patches and Plaques on Her ... - MDedge - April 15th, 2024 [April 15th, 2024]
- 9 Best Baby Eczema Creams of 2024 to Soothe Delicate Skin, According to Dermatologists - Allure - April 15th, 2024 [April 15th, 2024]
- QUIZ: Test Your Knowledge of Rosacea Etiology, Types, and Triggers - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Empowering Patients: Effective Dermatologic Treatment Selection for Hand and Feet AD - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- How To Treat Strawberry Legs, According To Dermatologists - Women's Health - April 15th, 2024 [April 15th, 2024]
- Rosacea Awareness Month: Resources to Share With Your Patients - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Understanding Drug Interactions in Systemic Treatment: Impact on Atopic Dermatitis Symptoms - Dermatology Times - April 15th, 2024 [April 15th, 2024]
- Derm In The News: March 31-April 6 - Dermatology Times - April 7th, 2024 [April 7th, 2024]
- Dr. Hillary Johnson-Jahangir of Forefront Dermatology Designated as a Candela Center of Excellence - PR Newswire - April 7th, 2024 [April 7th, 2024]
- How to Boost Your Immune System While Living With Psoriasis - Everyday Health - April 7th, 2024 [April 7th, 2024]
- Im a Harvard-trained dermatologist Ive followed 3 anti-aging rules for years, Im still a fan of a drug... - The US Sun - April 7th, 2024 [April 7th, 2024]
- Cosmetic Procedures for Psoriasis: Are They Safe? - Everyday Health - April 7th, 2024 [April 7th, 2024]
- FDA Approves Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum - Dermatology Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - The Mountaineer - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Islander News.com - January 8th, 2024 [January 8th, 2024]
- How To Get Rid Of Dark Spots On Your Face, Per Dermatologists - Women's Health - January 8th, 2024 [January 8th, 2024]
- POLL: What Are Your 2024 Dermatology Resolutions? - Dermatology Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - NBC Right Now - January 8th, 2024 [January 8th, 2024]
- Common perianal diseases and dermatology oddities - DVM 360 - January 8th, 2024 [January 8th, 2024]
- How To Keep Skin Hydrated And Protected In The Cold According To Dermatologists - Essence - January 8th, 2024 [January 8th, 2024]
- Retinol and Retinoids: 9 Things You Should Know Before Using - Vogue - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - pdclarion.com - January 8th, 2024 [January 8th, 2024]
- 8 Wintertime Skin Conditions to Look Out For - Health.com - January 8th, 2024 [January 8th, 2024]
- 9 Tips for Common Winter Skin Conditions, According to a Celeb Dermatologist - PEOPLE - January 8th, 2024 [January 8th, 2024]
- FDA Approval of ZELSUVMI Berdazimer Gel: A Revolutionary Achievement | Health News - Medriva - January 8th, 2024 [January 8th, 2024]
- Revolutionary Research Towards Acne Vaccine and Gene Editing Treatments - Medriva - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Corydon Times - January 8th, 2024 [January 8th, 2024]
- Dermatology treatments can become an expensive ongoing cost. - Hometown Register - January 8th, 2024 [January 8th, 2024]
- Rice Water for Hair Growth: Does It Really Work? - Health.com - January 8th, 2024 [January 8th, 2024]
- Dermatology Times 2023 In Review: NP and PA News - Dermatology Times - December 31st, 2023 [December 31st, 2023]
- Colorado dermatology company warning about cybersecurity threat where hacker gained access to health information - Summit Daily - December 31st, 2023 [December 31st, 2023]
- Reviewing the Top Dermatology Headlines of 2023 - Dermatology Times - December 31st, 2023 [December 31st, 2023]
- Dermatology Times 2023 In Review: Acne - Dermatology Times - December 31st, 2023 [December 31st, 2023]
- Skin to Skin: Getting to know UMs new dermatology club - The Miami Hurricane - December 22nd, 2023 [December 22nd, 2023]
- Advancements in Atopic Dermatitis: Insights from the 2024 Masterclasses in Dermatology Conference - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Schweiger Dermatology Group Acquires New Jersey Practices of NavaDerm Partners in Millburn and Englewood Cliffs - PR Newswire - December 22nd, 2023 [December 22nd, 2023]
- Spike in dermatology visits for skin problems seen during summer of wildfires - Medical Xpress - December 22nd, 2023 [December 22nd, 2023]
- More Images of Patients With Psoriasis Are Needed in Published Studies - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Practical Approaches to Atopic Dermatitis: Real-World Case Analyses - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- Schweiger Dermatology Group Expands into South Florida with Locations in West Palm Beach and Miami Beach - Tullahoma News and Guardian - December 22nd, 2023 [December 22nd, 2023]
- Receding Hairline: Symptoms, Causes, Treatments - Men's Health - December 22nd, 2023 [December 22nd, 2023]
- Podcast CE: Ophytrium in Dermatology: When, where and whys of using Douxo S3 topical therapies - DVM 360 - December 22nd, 2023 [December 22nd, 2023]
- POLL: Which Skin Cancer Drug Recently Received a Complete Response Letter From the FDA? - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- How to Treat Textured Skin, According to Dermatologists - Prevention Magazine - December 22nd, 2023 [December 22nd, 2023]
- Dermatology decoded with Dr. Davin Lim - manilastandard.net - December 22nd, 2023 [December 22nd, 2023]
- Arcutis' Zoryve bags 2nd FDA nod, this time as a foam to treat 'the great neglected disease in dermatology' - FiercePharma - December 22nd, 2023 [December 22nd, 2023]
- Moderna and Merck's V940 Plus Pembrolizumab Demonstrates Improvement in RFS and DMFS in Stage III/IV ... - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- From customised vitamin infusions to tech-driven dermatology: Skincare trends that dominated 2023 - The Indian Express - December 22nd, 2023 [December 22nd, 2023]
- Aptar Digital Health and Legit.Health Partner to Improve Patient Experience in Immuno-Dermatology - Healthcare Packaging - December 22nd, 2023 [December 22nd, 2023]
- Navigating Location Specific Treatment Selection and Topical Therapy Limitations - Dermatology Times - December 22nd, 2023 [December 22nd, 2023]
- POLL: What Percent of the Global Population is Estimated to Have ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Purple Heart Project Seeks to Provide Veterans With Access to ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Dermatology expert stresses importance of cytology and cultures - DVM 360 - November 18th, 2023 [November 18th, 2023]
- Shawn Kwatra, MD, Shares Highlights From the 12th World ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- The Weekly Roundup: November 12-17 - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Almirall, Absci Partner to Develop AI-Designed Therapies for ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- The Skin of Color Society Kicks Off a Season of Giving with its My ... - PR Newswire - November 18th, 2023 [November 18th, 2023]
- Clascoterone Cream in Patients With Acne: New Long-Term Data - Medpage Today - November 18th, 2023 [November 18th, 2023]
- Discovery of hemoglobin in the epidermis sheds new light on our ... - EurekAlert - November 18th, 2023 [November 18th, 2023]
- Global Assessment of Quality of Care for Patients With Malignant ... - Dermatology Advisor - November 18th, 2023 [November 18th, 2023]
- Effective Therapies for Atopic Dermatitis: Expert Recommendations ... - HealthDay - November 18th, 2023 [November 18th, 2023]
- Nonablative Lasers Offer a Gentle Approach to Healthy Skin - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Aging, Acne, and the Armamentarium: Hot Topics From the Science ... - Dermatology Times - November 18th, 2023 [November 18th, 2023]
- Prior Treatment Options and Outcomes for SD - MD Magazine - November 18th, 2023 [November 18th, 2023]
- Consequences of Lying on the Witness Stand: Are There Any for Dermatology Expert Witnesses? - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- The Cutaneous Manifestations of Drug Reactions Can Mimic Traumatic Injuries: Case Reports and the Potential Role ... - Cureus - October 27th, 2023 [October 27th, 2023]
- Robyn Siperstein, MD, FAAD: Initiating a Patient-First Dialogue in ... - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- Tralokinumab May Improve 52-Week Outcomes in Patients With Moderate to Severe Atopic Dermatitis - Dermatology Advisor - October 27th, 2023 [October 27th, 2023]
- How to Safely and Effectively Exfoliate Your Skin, According to Dermatologists - Allure - October 27th, 2023 [October 27th, 2023]
- Enhancing the Patient Experience Through Addressing Pain Points ... - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- Global Dermatology Collaboration and Licensing Deals and Agreements Analysis Report 2023 with Directory of Dermatology Deal Records Signed Since 2016... - October 27th, 2023 [October 27th, 2023]
- UNION therapeutics to present at 7th Annual Dermatology Drug ... - PR Newswire - October 27th, 2023 [October 27th, 2023]
- Tareen Dermatology Expands to Hudson, Wisconsin, Adding Sixth Location within the Hudson Medical Center - Yahoo Finance - October 27th, 2023 [October 27th, 2023]
- 4 Tips and Considerations for Selecting a Systemic Treatment for ... - Dermatology Times - October 27th, 2023 [October 27th, 2023]
- Yales Richard Edelson on what got him started in research for ... - The Cancer Letter - October 27th, 2023 [October 27th, 2023]